NasdaqGS - Nasdaq Real Time Price USD

Praxis Precision Medicines, Inc. (PRAX)

Compare

64.02

+0.87

+(1.38%)

At close: January 13 at 4:00:01 PM EST

62.48

-1.54

(-2.41%)

Pre-Market: 5:04:34 AM EST

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028 Study 1 of Essential3 program for ulixacaltamide in essential tremor (ET) on track for Q1 2025 interim analysis; NDA filing for ulixacaltamide expected in 2025 Enrollment in EMBOLD study of relutrigine cohort 2 is on track; targeting NDA filing in 2026 Vormatrigine ENERGY program advancing with read-outs of RADIANT in first half of 2025 and POWER1

GlobeNewswire yesterday

PRAX
+1.38%
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA at the Westin St. Francis Hotel on Wednesday, Janu

GlobeNewswire 7 days ago

PRAX
+1.38%
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those granted for SCN2A and SCN8A DEEs Praxis plans to initiate an all-DEE trial (EMERALD), inclusive of Dravet syndrome, in 1H2025 BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the de

GlobeNewswire 26 days ago

PRAX
+1.38%
Praxis Precision Medicines to Present at Upcoming December Investor Conferences

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024. Praxis management will be participating in a fireside chat at the Piper Sandler 36th Annual Healthca

GlobeNewswire last month

PRAX
+1.38%
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the American Epilepsy Society (AES) Annual Meeting, being held from December 6 to 10, 2024

GlobeNewswire last month

PRAX
+1.38%
Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Praxis Precision Medicines ( NASDAQ:PRAX ) Third Quarter 2024 Results Key Financial Results Net loss: US$51.9m (loss...

Simply Wall St. 2 months ago

PRAX
+1.38%
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...

Praxis Precision Medicines Inc (PRAX) reports robust financial health and significant progress in its clinical pipeline, despite some strategic delays.

GuruFocus.com 2 months ago

PRAX
+1.38%
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024. Praxis management will participate in a fireside chat at the Truist Securities BioPharma S

GlobeNewswire 2 months ago

PRAX
+1.38%
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of -36.82% and 42.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

PRAX
+1.38%
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epil

GlobeNewswire 2 months ago

PRAX
+1.38%
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024. The Company will host a live webc

GlobeNewswire 2 months ago

PRAX
+1.38%
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Praxis Precision...

Simply Wall St. 2 months ago

PRAX
+1.38%
Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals

We recently published a list of 10 Small Cap Stocks with High Potential. In this article, we are going to take a look at where Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stands against other small cap stocks with high potential. As we transition from a tumultuous summer in the financial markets, characterized by rising expectations for […]

Insider Monkey 3 months ago

PRAX
+1.38%
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?

Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 3 months ago

PRAX
+1.38%
GILD
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the presentation of a poster and platform talk showcasing its Phase 3 clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the Movement Disorders Society

GlobeNewswire 3 months ago

PRAX
+1.38%
Perceptive Advisors LLC Adjusts Stake in Praxis Precision Medicines Inc

On September 12, 2024, Perceptive Advisors LLC executed a significant transaction involving the shares of Praxis Precision Medicines Inc (NASDAQ:PRAX), a key player in the biopharmaceutical industry. Perceptive Advisors LLC, based at 51 Astor Place, New York, is renowned for its strategic investments primarily in the healthcare and financial services sectors. Perceptive Advisors is known for its keen focus on innovative companies within the healthcare sector, aligning with its investment philosophy of targeting life sciences and biotechnology advancements.

GuruFocus.com 3 months ago

PRAX
+1.38%
Praxis Precision Medicines to Participate in Upcoming Investor Conferences

BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be attending and presenting at two upcoming conferences: H.C. Wainwright 26th Annual Global Investment ConferenceFormat: Fireside ChatPresentation date and time: S

GlobeNewswire 4 months ago

PRAX
+1.38%
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Zacks 4 months ago

PRAX
+1.38%
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present preclinical and clinical data from three of its epilepsy programs at the International League Against Epilepsy (ILAE) 15th European Epilepsy Congress (EEC), b

GlobeNewswire 4 months ago

PRAX
+1.38%
IONS
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

On Tuesday, Praxis Precision Medicines Inc. (NASDAQ:PRAX) released topline results for its EMBOLD Phase 2 proof-of-concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. DEEs are characterized by seizures, encephalopathy (disturbance in brain function, and intellectual disability. Patients on relutrigine observed a placebo-adjusted reduction of 46% in countable motor seizures. Also Read: Value Of Praxis Precision Medicines’ Lead Program

Benzinga 4 months ago

PRAX
+1.38%

Performance Overview

Return	PRAX	S&P 500
YTD	-16.05%	-1.20%
1-Year	+47.61%	+22.00%
3-Year	-75.44%	+23.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting

Praxis Precision Medicines Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ...

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals

Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?

Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress

Perceptive Advisors LLC Adjusts Stake in Praxis Precision Medicines Inc

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Performance Overview